In a multicenter, head-to-head trial, donanemab demonstrated superiority over aducanumab for early symptomatic Alzheimer’s disease patients.
Article Limit Reached
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content